IRS1 (Ab-312) Antibody

What is IRS1 and what is its role in insulin signaling pathways?

IRS1 functions as a signaling adapter protein that participates in signal transduction from two prominent receptor tyrosine kinases: insulin receptor (INSR) and insulin-like growth factor I receptor (IGF1R). It plays a crucial role in development, growth, glucose homeostasis, and lipid metabolism . Upon phosphorylation by the insulin receptor, IRS1 functions as a signaling scaffold that propagates insulin action by binding to SH2 domain-containing proteins, including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2, or SHP2 . This binding initiates downstream signaling cascades, with the PI3K/AKT pathway being responsible for most insulin metabolic effects in cells, while the Ras/Raf/MEK/MAPK pathway regulates gene expression and cooperates with the PI3K pathway to control cell growth and differentiation .

What is the significance of phosphorylation at Serine 312 of IRS1?

Phosphorylation of IRS1 at Serine 312 (Ser312) has significant implications for insulin signaling and insulin resistance. Serine phosphorylation of IRS1 represents a key mechanism for insulin resistance. Specifically, Ser312 phosphorylation inhibits insulin action through disruption of IRS1 interaction with the insulin receptor . This phosphorylation site serves as a negative regulatory mechanism that attenuates insulin signaling. In pathological conditions like Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2), altered levels of P-serine 312-IRS-1 have been observed, suggesting its role as a biomarker for insulin resistance . The ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) is significantly elevated in these conditions, with AD showing higher levels than DM2 .

What applications are suitable for IRS1 (phospho S312) antibodies?

IRS1 (phospho S312) antibodies can be used in multiple research applications:

• Western Blot (WB): The primary application for detecting and quantifying phosphorylated IRS1 at Ser312 in protein samples, with recommended dilutions of 1:500-1:2000 .

• Immunohistochemistry (IHC): For visualizing phosphorylated IRS1 in tissue sections, including both paraffin-embedded (IHC-p) and frozen sections (IHC-f), with recommended dilutions of 1:50-1:200 .

• Immunofluorescence/Immunocytochemistry (IF/ICC): For cellular localization studies of phosphorylated IRS1, with recommended dilutions of 1:100-1:500 .

• ELISA: For quantitative measurement of phosphorylated IRS1 levels in various sample types .

These applications allow researchers to investigate IRS1 phosphorylation in different experimental models and clinical samples, providing insights into insulin signaling and resistance mechanisms.

How should I validate the specificity of IRS1 (phospho S312) antibodies?

Validating antibody specificity is crucial for reliable experimental results. For IRS1 (phospho S312) antibodies, consider the following validation approaches:

• Phosphatase treatment: Treat half of your sample with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show diminished signal in the treated sample.

• Blocking peptide experiments: Use the specific phosphopeptide immunogen to compete with antibody binding. Commercial IRS1 (Ser312) peptides (such as MBS9615627) can be used for blocking the activity of IRS1 (Ser312) antibodies (like MBS9601044) .

• Positive and negative controls: Include samples known to have high levels of Ser312 phosphorylation (e.g., insulin-resistant cell models) and samples with low phosphorylation (e.g., serum-starved cells).

• Compare with pan-IRS1 antibody: Run parallel blots with both phospho-specific and total IRS1 antibodies to confirm that the observed changes are in phosphorylation status rather than total protein levels.

• Verify molecular weight: Confirm that the detected band appears at the expected molecular weight (observed: 180 kDa; predicted: 132 kDa) .

How does IRS1 Ser312 phosphorylation status correlate with insulin resistance in different tissues?

IRS1 Ser312 phosphorylation serves as a molecular indicator of insulin resistance across various tissues. In insulin-responsive tissues, elevated Ser312 phosphorylation correlates with diminished insulin signaling efficiency. This correlation varies by tissue type:

• Neural tissue: In Alzheimer's disease, brain insulin resistance is characterized by significantly elevated P-serine 312-IRS-1 levels compared to control subjects . This pattern extends beyond directly affected brain regions, suggesting a systemic dysregulation of insulin signaling pathways.

• Metabolic tissues: In type 2 diabetes, skeletal muscle, adipose tissue, and liver show increased IRS1 Ser312 phosphorylation, which correlates with reduced glucose uptake and metabolism.

• Tissue-specific variations: The magnitude of IRS1 Ser312 hyperphosphorylation and its correlation with functional insulin resistance can vary significantly between tissues, with brain tissue in AD showing particularly pronounced changes compared to peripheral tissues in DM2 .

When designing experiments to investigate tissue-specific patterns, researchers should consider using tissue-matched controls and normalizing phosphorylation levels to total IRS1 expression to account for baseline differences in IRS1 abundance across tissues.

What is the relationship between IRS1 Ser312 phosphorylation and the pathophysiology of Alzheimer's disease?

Research indicates a complex relationship between IRS1 Ser312 phosphorylation and Alzheimer's disease (AD) pathophysiology:

• Diagnostic biomarker potential: Exosomal levels of P-serine 312-IRS-1 and the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) are significantly different in AD patients compared to control subjects . Longitudinal studies have shown these differences can be detected 1 to 10 years before clinical diagnosis, suggesting value as early biomarkers .

• Differential diagnosis: The levels of insulin resistance factor (R) for AD are significantly higher than those for type 2 diabetes mellitus (DM2) or frontotemporal dementia (FTD), highlighting a potentially unique pattern of insulin signaling dysregulation in AD .

• Classification accuracy: Stepwise discriminant modeling using these phosphorylation markers showed correct classification of 100% of patients with AD, 97.5% of patients with DM2, and 84% of patients with FTD, demonstrating their specificity for different neurodegenerative conditions .

• Mechanistic links: Hyperphosphorylation of IRS1 at Ser312 in AD may contribute to impaired neuronal insulin signaling, reduced glucose metabolism, and compromised synaptic plasticity and neuronal survival, potentially linking metabolic dysfunction to cognitive decline.

These findings suggest that IRS1 Ser312 phosphorylation may represent both a biomarker and a mechanistic contributor to AD pathophysiology, identifying a potential target for therapeutic intervention.

How can I optimize sample preparation to preserve phosphorylation status of IRS1?

Preserving the phosphorylation status of IRS1 during sample preparation is critical for accurate analysis. Here's a methodological approach:

• Rapid tissue/cell collection: Minimize the time between tissue collection and processing to prevent dephosphorylation by endogenous phosphatases. For cell culture, quick washing with ice-cold PBS followed by immediate lysis is recommended.

• Phosphatase inhibitors: Include a comprehensive phosphatase inhibitor cocktail in all buffers used during sample preparation. This should include inhibitors targeting serine/threonine phosphatases (e.g., okadaic acid, calyculin A) and tyrosine phosphatases (e.g., sodium orthovanadate).

• Lysis buffer composition: Use a lysis buffer containing:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% NP-40 or Triton X-100

  • 0.5% sodium deoxycholate

  • 1 mM EDTA

  • 1 mM EGTA

  • Complete phosphatase inhibitor cocktail

  • Protease inhibitor cocktail

  • 1 mM DTT or β-mercaptoethanol

• Temperature control: Maintain samples at 4°C throughout processing to minimize phosphatase activity.

• Protein denaturation: Add SDS sample buffer and heat immediately after lysis to denature phosphatases.

• Storage considerations: If immediate analysis is not possible, snap-freeze lysates in liquid nitrogen and store at -80°C. Avoid repeated freeze-thaw cycles as these can affect phosphorylation status.

• Validation: Include control samples with known phosphorylation states to confirm preservation during your specific protocol.

This methodological approach ensures that the phosphorylation status of IRS1 at Ser312 is maintained throughout sample preparation, allowing for more accurate assessment in subsequent analyses.

What are the key considerations for quantifying the ratio of different IRS1 phosphorylation states?

Accurate quantification of different IRS1 phosphorylation states, particularly the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R), requires careful methodological considerations:

• Antibody selection and validation:

  • Use highly specific antibodies that recognize only the phosphorylated form of interest

  • Validate antibody specificity using phosphatase treatments and competing peptides

  • Ideally, use antibodies raised against identical species to minimize cross-reactivity variations

• Sample normalization strategies:

  • Normalize phospho-signals to total IRS1 levels in parallel samples

  • Use consistent loading controls (e.g., GAPDH, β-actin) across all samples

  • Consider using recombinant phosphorylated standards for absolute quantification

• Detection methods:

  • For Western blotting: Use quantitative fluorescent secondary antibodies rather than chemiluminescence for wider linear range

  • For ELISA: Develop sandwich ELISAs with capture antibodies against total IRS1 and detection antibodies against specific phosphorylation sites

  • For multiplex analysis: Consider bead-based multiplex assays to simultaneously measure multiple phosphorylation sites

• Data analysis approaches:

  • Calculate ratios only after background subtraction

  • Apply appropriate statistical methods for ratio data, which may not follow normal distribution

  • Account for potential non-linearity in signal response, especially at extreme values

• Technical replicates:

  • Include at least three technical replicates for each biological sample

  • Report both absolute values and normalized ratios with appropriate measures of variation

In disease-related research, such as AD and DM2 studies, the P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 ratio has demonstrated significant diagnostic potential, with mean values of 92.2 ± 5.34 for AD compared to 19.4 ± 1.44 for age-matched controls . This methodological approach ensures reliable quantification of this diagnostically relevant parameter.

How can IRS1 (phospho S312) antibodies be used in Alzheimer's disease research protocols?

IRS1 (phospho S312) antibodies offer valuable tools for investigating the neurometabolic aspects of Alzheimer's disease:

• Exosomal biomarker analysis:

  • Isolate neural-derived exosomes from plasma or CSF samples

  • Quantify P-serine 312-IRS-1 levels using ELISA or Western blot

  • Calculate the P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 ratio (insulin resistance factor, R)

  • Compare values to established reference ranges (AD patients: R≈92.2 ± 5.34; Controls: R≈19.4 ± 1.44)

• Brain tissue analysis:

  • Perform immunohistochemistry on post-mortem brain sections to map the distribution of phosphorylated IRS1

  • Co-stain with Aβ, tau, and other AD markers to investigate spatial relationships

  • Compare phosphorylation patterns across brain regions with differential vulnerability to AD pathology

• Longitudinal monitoring:

  • Track exosomal P-serine 312-IRS-1 levels over time in at-risk populations

  • Correlate changes with cognitive assessments and other biomarkers

  • Use as a surrogate endpoint in intervention trials targeting insulin signaling

• Drug screening applications:

  • Evaluate candidate compounds for their ability to normalize IRS1 phosphorylation patterns

  • Develop high-throughput assays using IRS1 (phospho S312) antibodies to screen compound libraries

  • Validate hits in progressively complex systems (cells → organoids → animal models)

This methodological framework leverages the finding that exosomal levels of P-serine 312-IRS-1 can differ significantly between AD patients and controls up to 10 years before clinical diagnosis , positioning it as both a potential early diagnostic marker and a mechanistic target for intervention.

What experimental controls are essential when investigating IRS1 phosphorylation in insulin resistance models?

Rigorous experimental design for studying IRS1 phosphorylation in insulin resistance models requires careful implementation of multiple controls:

• Treatment-related controls:

  • Positive controls: Include samples treated with known inducers of Ser312 phosphorylation (e.g., TNF-α, high glucose, free fatty acids)

  • Negative controls: Include samples treated with insulin sensitizers (e.g., metformin, thiazolidinediones) or PI3K/mTOR inhibitors

  • Time course controls: Collect samples at multiple time points to capture dynamic phosphorylation changes

• Phosphorylation status controls:

  • Phosphatase-treated samples: Process parallel samples with lambda phosphatase to verify phospho-specificity

  • Multiple phosphorylation sites: Assess several IRS1 phosphorylation sites simultaneously (e.g., Ser307, Ser636/639) to establish phosphorylation patterns

  • Ratio controls: Always measure both inhibitory (serine) and stimulatory (tyrosine) phosphorylation to calculate meaningful ratios

• Antibody validation controls:

  • Peptide competition: Use phosphopeptides to block antibody binding

  • Antibody dilution series: Perform titration to ensure working in the linear range

  • Secondary-only controls: Verify absence of non-specific binding

• Physiological response controls:

  • Insulin stimulation: Include acute insulin challenge to assess signaling responsiveness

  • Downstream markers: Measure AKT phosphorylation and glucose uptake to correlate IRS1 phosphorylation with functional outcomes

  • Recovery experiments: Demonstrate reversibility of phosphorylation changes with appropriate interventions

This comprehensive control strategy ensures that observed changes in IRS1 Ser312 phosphorylation accurately reflect the insulin resistance state being modeled and provides a foundation for interpreting the functional significance of these modifications.

How do different commercial IRS1 (phospho S312) antibodies compare in research applications?

When selecting an IRS1 (phospho S312) antibody for research, understanding the comparative properties of available options is essential for experimental success:

Key considerations for application-specific selection:

• For Western blotting: All three antibodies are suitable, with similar recommended dilutions for phospho-specific options. Consider using the Abcam or MyBioSource antibodies when specifically investigating phosphorylation status.

• For immunohistochemistry/immunofluorescence: The Affinity Biosciences and MyBioSource antibodies offer validated protocols, with the latter being phospho-specific for more targeted analysis of Ser312 phosphorylation.

• For multiplex analysis: When investigating both total and phosphorylated IRS1, consider using the Affinity Biosciences antibody for total IRS1 detection in combination with a phospho-specific antibody from Abcam or MyBioSource.

• For cross-species studies: The Affinity Biosciences and MyBioSource antibodies offer broader species reactivity, making them more versatile for comparative studies across different model organisms.

This comparative analysis highlights the importance of selecting the appropriate antibody based on the specific research question, experimental design, and biological system under investigation .

What are the emerging applications of IRS1 (phospho S312) analysis in neurodegenerative disease research?

The study of IRS1 phosphorylation is revealing new dimensions in neurodegenerative disease research:

• Diagnostic biomarker development:

  • The ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) demonstrates remarkable diagnostic potential, with stepwise discriminant modeling showing correct classification of 100% of AD patients, 97.5% of DM2 patients, and 84% of FTD patients .

  • Longitudinal studies reveal these markers can be detected 1-10 years before clinical diagnosis, suggesting utility for preclinical detection .

• Differential diagnosis applications:

  • The significantly higher insulin resistance factor (R) in AD compared to DM2 or FTD provides a molecular signature that could help distinguish these conditions .

  • This approach may be particularly valuable for identifying AD pathology in the presence of comorbid metabolic disorders.

• Brain-peripheral tissue connections:

  • Neural-derived exosomes in blood provide a window into brain IRS1 phosphorylation status without requiring invasive procedures.

  • This approach enables studies of brain-specific insulin resistance patterns in living patients and longitudinal monitoring during clinical trials.

• Therapeutic target validation:

  • IRS1 Ser312 phosphorylation represents a potential target for drugs aiming to restore proper insulin signaling in neurodegenerative diseases.

  • Quantifying changes in phosphorylation status provides a mechanistic biomarker to assess target engagement in clinical trials.

• Integration with other biomarkers:

  • Combining IRS1 phosphorylation analysis with established AD biomarkers (Aβ, tau, neurofilament light) and metabolic markers may enhance diagnostic accuracy and patient stratification.

  • Multi-modal approaches could identify subgroups of patients most likely to benefit from metabolism-targeted interventions.

These emerging applications position IRS1 (phospho S312) analysis at the intersection of metabolic dysfunction and neurodegeneration, offering new paradigms for understanding disease mechanisms and developing targeted interventions.

How can I optimize Western blotting protocols for detecting IRS1 phosphorylation?

Optimizing Western blotting for IRS1 phosphorylation detection requires addressing several technical challenges:

• Sample preparation:

  • Use fresh samples whenever possible

  • Include both phosphatase and protease inhibitors in lysis buffers

  • Maintain samples at 4°C throughout processing

  • Consider using phospho-protein enrichment techniques for low-abundance samples

• Gel electrophoresis considerations:

  • Use lower percentage gels (6-8%) or gradient gels to resolve high molecular weight IRS1 (180 kDa observed)

  • Load adequate protein (30-50 μg total protein per lane) to detect phosphorylation sites

  • Include molecular weight markers that span the appropriate range

• Transfer optimization:

  • Use wet transfer methods for large proteins like IRS1

  • Extend transfer time (overnight at low voltage) for complete transfer

  • Consider using transfer buffers optimized for high molecular weight proteins

  • Verify transfer efficiency with reversible staining before blocking

• Antibody incubation:

  • Block thoroughly (5% BSA is often preferred over milk for phospho-epitopes)

  • Use recommended antibody dilutions (1:500-1:2000 for Western blot)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure adequate washing between steps (5-6 washes of 5-10 minutes each)

• Detection strategies:

  • Consider fluorescent secondary antibodies for more quantitative results

  • Use enhanced chemiluminescence with extended exposure times if needed

  • For multiplex detection, strip and reprobe membranes sequentially rather than simultaneously

• Controls and normalization:

  • Always include phosphorylation state controls (e.g., insulin-stimulated vs. basal)

  • Run parallel blots for total IRS1 and phospho-IRS1

  • Normalize phospho-signals to total protein rather than housekeeping genes

Following these methodological optimizations will improve the detection of IRS1 phosphorylation states in Western blotting applications, enabling more reliable quantification of insulin resistance markers.

What are the key considerations for quantifying IRS1 phosphorylation in clinical samples?

Accurate quantification of IRS1 phosphorylation in clinical samples presents unique methodological challenges:

• Pre-analytical considerations:

  • Standardize sample collection procedures (time of day, fasting status, medication status)

  • Process samples rapidly after collection to preserve phosphorylation status

  • Establish consistent storage conditions (-80°C, avoid freeze-thaw cycles)

  • Document pre-analytical variables for each sample to identify potential confounders

• Exosome isolation techniques:

  • For blood-based analysis, isolate neural-derived exosomes using neural-specific markers

  • Validate exosome isolation methods for consistency and purity

  • Confirm exosome identity through size analysis and marker verification

  • Normalize results to exosome number or total exosomal protein

• Quantification methods:

  • ELISA methods provide more quantitative results than Western blotting

  • Develop and validate sandwich ELISAs specific for phosphorylated epitopes

  • Include calibration curves using recombinant phosphorylated standards

  • Implement rigorous quality control procedures (inter-assay and intra-assay controls)

• Clinical reference ranges:

  • Establish age-matched and gender-matched reference ranges

  • Account for comorbidities that might affect baseline phosphorylation

  • Consider longitudinal changes rather than absolute values when possible

  • Use the established ratio values as references (AD: R≈92.2 ± 5.34; Controls: R≈19.4 ± 1.44)

• Integration with clinical data:

  • Correlate phosphorylation measurements with clinical variables

  • Adjust for potential confounders in statistical analyses

  • Consider developing composite biomarker scores incorporating multiple phosphorylation sites

• Assay validation for clinical use:

  • Assess analytical sensitivity, specificity, precision, and accuracy

  • Determine the minimum sample size required for reliable results

  • Validate across multiple testing sites if developing for clinical applications

These methodological considerations ensure that quantification of IRS1 phosphorylation in clinical samples is standardized, reliable, and clinically meaningful, particularly when used as biomarkers for conditions like Alzheimer's disease .

What is the future research direction for IRS1 (phospho S312) antibodies in metabolic and neurodegenerative disease studies?

The continuing development of IRS1 (phospho S312) antibody applications is poised to advance several promising research directions:

• Early detection and differential diagnosis:

  • Refinement of blood-based exosomal biomarker panels using IRS1 phosphorylation patterns

  • Development of point-of-care testing platforms for accessible screening

  • Creation of diagnostic algorithms combining IRS1 phosphorylation with other biomarkers

• Mechanism elucidation:

  • Investigation of bidirectional relationships between IRS1 phosphorylation and disease pathology

  • Exploration of cell type-specific insulin resistance patterns in complex tissues

  • Examination of interactions between genetic risk factors and IRS1 phosphorylation states

• Therapeutic development:

  • Screening of compounds that normalize IRS1 phosphorylation patterns

  • Validation of IRS1 phosphorylation as a surrogate endpoint in clinical trials

  • Development of targeted approaches to modulate specific phosphorylation sites

• Technological innovations:

  • Single-cell analysis of IRS1 phosphorylation states

  • In vivo imaging of IRS1 phosphorylation dynamics

  • Artificial intelligence applications for pattern recognition in phosphorylation profiles

• Translational applications:

  • Implementation of standardized assays in clinical laboratory settings

  • Development of risk stratification tools based on phosphorylation profiles

  • Creation of personalized intervention strategies based on individual insulin resistance patterns